Federated Hermes' Q2 13F shows a clear rotation into mega-cap tech (Apple, Amazon, Microsoft, Nvidia) and energy (Chevron, Exxon), funded by trimming consumer staples and some financials. The new positions in Genmab, Credo Technology, and Atlassian suggest a growth tilt. Monitor next quarter's 13F to see if this rotation accelerates or reverses, especially given the strong earnings backdrop and record AUM.
Price Chart
Executive Summary
Federated Hermes filed its Q2 2026 13F, showing a $69.6B equity portfolio with significant new positions in Genmab ($39.1M), Credo Technology ($62.6M), and Atlassian ($48.6M). The firm increased stakes in major tech (Apple, Amazon, Microsoft) and energy (Chevron, Exxon) while trimming consumer staples (Coca-Cola, Altria) and some financials. This filing follows a strong Q2 earnings beat (EPS $1.38 vs $1.19 consensus) and record AUM of $911.6B, suggesting the portfolio shifts reflect reinvestment of strong cash flows into growth and tech names.
Key Facts
- Total portfolio value: ~$69.6 billion as of June 30, 2026
- New large positions include Genmab ($39.1M), Credo Technology ($62.6M), Atlassian ($48.6M), Booking Holdings ($739K), and Cheniere Energy ($1.25M)
- Top holdings by value: Apple ($1.3B), Alphabet ($909M), Microsoft ($1.5B), Amazon ($419M), Nvidia ($1.2B)
- Significant increases: Apple (+$1.1B), Amazon (+$1.0B), Microsoft (+$1.5B), Chevron (+$174M), Duke Energy (+$149M)
- Notable reductions: Coca-Cola (-$3.2M), Altria (-$106M), Amcor (-$188M), British American Tobacco (-$185M), American Tower (-$156M)
- Filed 13 days after a strong Q2 earnings report (EPS beat by 16%, revenue +18% YoY, record AUM)
Financial Impact
Portfolio value of ~$69.6B with significant rotation into mega-cap tech and energy, funded by trimming consumer staples and select financials
Risk Factors
- Portfolio shifts may reflect fund flows rather than active conviction
- Concentration in mega-cap tech increases single-stock risk
- New biotech position (Genmab) adds binary risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 13F-HR Filing (Primary) | 0001623632-26-001176 |
| Document: 0001623632-26-001176-index.html | 0001623632-26-001176 |
| Document: 0001623632-26-001176.txt | 0001623632-26-001176 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 10w ago | 13F-HR | $63.00 | awaiting T+60 | — | $56.55 (−10.24%) |
Jul 30, 2026 12w ago | 8-K | $59.96 $56.93 | ▼ −5.05% | ▼ −7.51% | $56.55 (−5.69%) |
Jul 30, 2026 12w ago | Press Release | $59.96 $56.93 | ▼ −5.05% | ▼ −7.51% | $56.55 (−5.69%) |
Jun 23, 2026 17w ago | 144 | $56.38 $56.36 | ▼ −0.04% | ▼ −2.87% | $56.55 (+0.30%) |
Mar 5, 2026 33w ago | Insider Cluster | $56.48 $55.89 | ▼ −1.05% | ▼ −12.35% | $56.55 (+0.12%) |
Mar 5, 2026 33w ago | Insider Cluster | $56.48 $55.89 | ▼ −1.05% | ▼ −12.35% | $56.55 (+0.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers